ACE and chronic kidney disease: A retrospective analysis of a clinical study found that SGLT2 inhibitors combined with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers still had the function of protecting renal function, compared with the group without SGLT2 inhibitors, and did not increase the incidence of acute renal adverse events in CKD patients (41).